Seoul
Chief MD, Gangnam
Duk-ha Kim
The trust our patients have placed in this clinic was built on conviction and principle. We intend to hold to both, unchanged, through the next hundred years.
Botulinum toxin off-label evidence guide
Scalp Toxin
“Scalp toxin” is a name used for botulinum toxin injections placed in the scalp for at least three different purposes — excess sweating, oiliness (seborrhea), and hair thinning — and none of them appears as a scalp indication on the U.S. therapeutic BOTOX label, whose approved hyperhidrosis coverage is written for the axilla. The evidence behind each purpose also differs: a 2025 review of 40 reports and 689 patients described a consistently reported effect for scalp sweating and an effect described as mild or not statistically significant for androgenetic hair loss, so the purpose named at consultation changes what evidence actually applies.
- Approved scalp indication
- None in the sources cited here — the U.S. therapeutic BOTOX label’s hyperhidrosis indication covers the axilla only
- Korean product labels
- Nabota and Meditoxin carry no sweating indication on their own labels, on the scalp or elsewhere
- Evidence base
- 2023 review: 24 reports, 309 patients. 2025 review: 40 reports, 689 patients
- Evidence differs by purpose
- Consistently reported effect for scalp sweating; mild or not statistically significant for androgenetic hair loss
Is “Scalp Toxin” one procedure with one approval behind it?
No. “Scalp toxin” is a name used for botulinum toxin injections placed in the scalp for at least three different purposes — excess sweating, oiliness (seborrhea), and hair thinning — and the sources cited here describe none of those purposes as carrying a scalp-specific approval on the U.S. therapeutic BOTOX label. What sits behind the name changes case by case, so the purpose named at consultation matters more than the single term on a treatment menu.
Why do sweating, oiliness and hair thinning end up under one name?
Because all three involve injecting the same toxin into the scalp, even though the biological target differs: sweat glands for excess sweating, sebaceous glands for oiliness, and hair follicles and surrounding muscle for hair thinning. A 2025 review of 40 reports covering 689 patients found androgenetic hair loss made up about 79.5% of the reported purposes, scalp seborrhea about 10%, and facial hyperhidrosis about 9%. Grouping these under one name on a treatment menu can make a hair-thinning purpose look as established as a sweating purpose, when the evidence for each is different.
Sources: Toxins 2025;17(4):163 — review of botulinum toxin for scalp indications (40 reports, 689 patients)
What does the toxin injection actually act on?
For sweating, the mechanism follows the one described on the therapeutic BOTOX label: the toxin blocks the release of acetylcholine at the nerve terminal, and sweat glands are driven by acetylcholine-carrying nerve fibres, so less signal reaches them. That description is written for the label’s approved axillary indication rather than for the scalp specifically. For oiliness and hair thinning, the sources cited on this page do not describe a mechanism, so this page states only what is established for sweat glands and leaves the other two purposes without a mechanism claim.
Does any label approve a scalp indication for this toxin?
No indication for the scalp appears in the sources cited on this page. The U.S. therapeutic BOTOX label’s approved hyperhidrosis indication is written for the axilla, and the two reviews cited here catalogue case reports and small studies rather than a regulatory approval record for the scalp. A treatment can still be discussed and offered without that approval existing, but the distinction between an approved indication and a reported use is exactly what decides how much weight the evidence carries.
Sources: FDA label — BOTOX (onabotulinumtoxinA) therapeutic prescribing information, hyperhidrosis indication limited to the axillaeDermatol Surg 2023;49(11):1023-1026 — systematic review of botulinum toxin for scalp indications (24 reports, 309 patients)Toxins 2025;17(4):163 — review of botulinum toxin for scalp indications (40 reports, 689 patients)
What does the U.S. label say about areas beyond the underarm?
The label’s hyperhidrosis indication carries a Limitations of Use statement: "The safety and effectiveness of BOTOX for hyperhidrosis in other body areas have not been established." The scalp is not named individually, but it falls within the "other body areas" that statement covers rather than within the axilla the indication is written for. The sentence describes what the approval record does not establish; it does not say a scalp injection is unavailable, only that this label is not the basis for it.
Do Korean-made toxin products carry a sweating indication at all?
For the two Korean-made products commonly used on clinic menus, Nabota and Meditoxin, the approved indications and usage printed on their own labels do not include a sweating indication in the first place. That is a separate point from the scalp question above: before even asking whether the scalp is covered, neither product’s own label carries hyperhidrosis as an approved use anywhere on the body. If either is the product proposed for a scalp injection, the injection sits outside its label on two counts at once — the product’s own indications and the body area.
Does an off-label injection mean something illegal is happening?
No. Off-label means a clinician is using an approved medicine outside the indication printed on its own label, which is legal and common in medicine generally; it is not the same as using an unapproved or counterfeit product. What changes off-label is not legality but the evidence behind the decision: the U.S. label’s own approval process does not stand behind a scalp use, so the reasoning for offering it rests instead on the reports and reviews discussed on this page, which sit at a different, generally lower tier of evidence than an approved indication.
What did the 2023 systematic review report?
A systematic review published in Dermatologic Surgery in 2023 identified 24 reports covering 309 patients across botulinum toxin use for scalp indications, made up of a mix of case reports, clinical trials and case series. The authors described the quality of the underlying evidence as highly variable and noted that most of it came from small observational studies rather than large controlled trials. That description applies to the evidence base as a whole, across the different purposes it covers, rather than to any single purpose in isolation.
What did the 2025 review add to that picture?
A 2025 review in the journal Toxins covered a larger set: 40 reports and 689 patients across the same general area of scalp indications. It reported the purpose breakdown noted above — androgenetic hair loss at about 79.5%, scalp seborrhea at about 10%, facial hyperhidrosis at about 9% — and it described the reported outcomes as differing by purpose rather than uniform across the set.
Sources: Toxins 2025;17(4):163 — review of botulinum toxin for scalp indications (40 reports, 689 patients)
What does the evidence say about hair loss specifically?
The 2025 review described the reported effect on androgenetic hair loss as mild or not statistically significant. That is a description of what the review found for that one purpose, not a statement about scalp toxin use as a whole, and it is not a description of a benefit that can be promised at consultation.
Sources: Toxins 2025;17(4):163 — review of botulinum toxin for scalp indications (40 reports, 689 patients)
What does the evidence say about scalp sweating specifically?
For scalp sweating, the same 2025 review described a consistently reported effect across the cases it covered, in contrast with the hair-loss purpose above. A consistently reported effect drawn from case reports and small studies is still evidence from an unapproved use rather than from the controlled trials behind an approved label, so it remains a different kind of evidence from the axillary hyperhidrosis indication that is actually approved.
Sources: Toxins 2025;17(4):163 — review of botulinum toxin for scalp indications (40 reports, 689 patients)
Where does the seborrhea purpose sit in the evidence?
The 2025 review counted scalp seborrhea at about 10% of the reported purposes across its 40 reports, alongside hair loss and facial hyperhidrosis. That places it within the same reported literature as the other two purposes; the purpose breakdown records a share for it without pairing that share with the kind of outcome description given separately for hair loss and scalp sweating above.
Sources: Toxins 2025;17(4):163 — review of botulinum toxin for scalp indications (40 reports, 689 patients)
How is this different from the axillary hyperhidrosis toxin already covered on this site?
Underarm hyperhidrosis toxin, covered elsewhere on this site, sits on an approved indication on the U.S. therapeutic BOTOX label, with a defined patient description and label-based dosing. Scalp toxin, for any of its three purposes, has no equivalent approval in the sources cited here; the case for it is built from the reports and reviews above rather than from a label. The two pages describe different evidence tiers under a similar-sounding name, and that difference — an approved indication versus a reported use — is the reason this page exists separately rather than as a variation of the axillary one.
Sources: FDA label — BOTOX (onabotulinumtoxinA) therapeutic prescribing information, hyperhidrosis indication limited to the axillaeDermatol Surg 2023;49(11):1023-1026 — systematic review of botulinum toxin for scalp indications (24 reports, 309 patients)Toxins 2025;17(4):163 — review of botulinum toxin for scalp indications (40 reports, 689 patients)
How long does the effect last?
Neither review cited on this page reports how long an observed effect lasted, and no source here sets a scalp-specific retreatment interval the way the axillary hyperhidrosis indication does for its own approved use. What the 2025 review does report is that the effect differs by purpose: a consistently reported effect for scalp sweating against one described as mild or not statistically significant for androgenetic hair loss — and an effect that is small or inconsistent to begin with is a different question from how long a clear effect holds. Because no scalp label exists, there is also no established dose or schedule behind any duration claim; that combination of product, dose and purpose is decided case by case rather than set by a label. Confirm at consultation which purpose is being targeted, what product and dose are proposed, and what the clinic bases its proposed retreatment interval on.
Sources: FDA label — BOTOX (onabotulinumtoxinA) therapeutic prescribing information, hyperhidrosis indication limited to the axillaeToxins 2025;17(4):163 — review of botulinum toxin for scalp indications (40 reports, 689 patients)
What area-related considerations come with injecting the scalp rather than the underarm?
The scalp sits close to the forehead and temple muscles and to nerves that run through the area, a different anatomical neighbourhood from the underarm the approved indication is written for. The sources cited on this page do not set out a scalp-specific side-effect profile, so this page does not attach numbers to one. What they do support is that the injection site changes what sits nearby, which is why headache and localized muscle weakness near the injection points are the kind of area-specific question worth raising with the injecting clinician — alongside the clinician’s own experience and the product label — before agreeing to treatment.
Why does the product and the dose matter more than the phrase “scalp toxin”?
The case reports underlying the reviews cited here are built around a specific product and a specific dose in each case, not around a generic phrase. Because scalp use sits outside the labelled indication, there is no single label dictating a standard dose the way the axillary indication does. Two clinics offering “scalp toxin” could be using different products, at different doses, for a different one of the three purposes described above, and none of that is visible from the name alone. Asking for the product name and the dose is how those variables become visible before deciding.
Sources: Dermatol Surg 2023;49(11):1023-1026 — systematic review of botulinum toxin for scalp indications (24 reports, 309 patients)Toxins 2025;17(4):163 — review of botulinum toxin for scalp indications (40 reports, 689 patients)
What should be confirmed before agreeing to a scalp toxin injection?
Start with the purpose: whether the injection targets sweating, oiliness or hair thinning, because the evidence differs by purpose as described above. Then confirm the product name and the dose being used, since neither is standardized by a scalp-specific label. Ask what the clinic’s plan is if an adverse reaction appears, given that this use sits outside the approved indication rather than under label-based guidance. Disclose previous botulinum toxin treatment with its product and date, neuromuscular conditions, current medicines, allergies, and pregnancy or breastfeeding before the appointment.
Does the reported evidence change with the treatment purpose?
This table lines up three different purposes side by side rather than ranking them, and none of the three is an approved indication in the sources cited here. The only body area the U.S. label approves for hyperhidrosis is the axilla, so every purpose in this table sits outside that approval.
| Purpose | 2025 review share (of 40 reports, 689 patients) | Reported outcome | What this page can state |
|---|---|---|---|
| Sweating (scalp / facial hyperhidrosis) | The purpose breakdown lists facial hyperhidrosis at about 9%; the same review separately describes an outcome for scalp sweating | A consistently reported effect across the cases the review describes for scalp sweating | Reported-use evidence from case-level literature, not an approved indication in any source cited on this page |
| Scalp seborrhea (oiliness) | About 10% of the reported purposes in the same review | The purpose breakdown records a share for this purpose without pairing it with the kind of outcome description given for the other two | Ask what specific change is being described for this purpose before treatment |
| Androgenetic hair loss | About 79.5% of the reported purposes — the largest share in the review | Described as mild or not statistically significant | The largest reported purpose paired with the weakest reported outcome among the three |
This table summarises what one 2025 review reported by purpose. It is not a ranking of clinics or products, and none of these three rows describes an approved indication — the U.S. label’s only approved hyperhidrosis site is the axilla.
Sources: FDA label — BOTOX (onabotulinumtoxinA) therapeutic prescribing information, hyperhidrosis indication limited to the axillaeToxins 2025;17(4):163 — review of botulinum toxin for scalp indications (40 reports, 689 patients)
Medical care at Abijou
Care is provided by the medical team at the branch you select. These clinicians lead the three branches linked from this guide; confirm the doctor assigned to your visit with that branch.
Chief MD, Myeongdong
Cheol-su Yoon
I want to be thinking about how the patient feels right up to the last moment of the procedure.
Chief MD, Hongdae
Jae-wook Kim
I will give my best with the attentiveness to catch even the smallest change.
Listed branch medical team — not a medical-review byline for this article.
Frequently asked questions
What is “Scalp Toxin”?
It is a menu name for botulinum toxin injections placed in the scalp, used for at least three different purposes — excess sweating, oiliness (seborrhea), and hair thinning — none of which carries a scalp-specific approval on the U.S. therapeutic BOTOX label. Which purpose is meant changes what evidence applies, so the purpose matters more than the single name.
Does the U.S. therapeutic BOTOX label approve a scalp indication?
No. Its approved hyperhidrosis indication is written for the axilla, and a Limitations of Use statement on that same label says safety and effectiveness for hyperhidrosis in other body areas have not been established — the scalp falls within that unestablished territory rather than within the approved one.
Are Korean-made toxin products such as Nabota or Meditoxin approved for sweating anywhere on the body?
No. The approved indications and usage printed on their own labels do not include a sweating indication in the first place, so the scalp question does not even arise for these two products the way it does for the therapeutic BOTOX label.
Does off-label mean the injection is illegal?
No. Off-label means a clinician is using an approved medicine outside the indication printed on its own label, which is legal and common in medicine broadly; what changes is the evidence behind the decision, not its legality.
Why does it matter whether the purpose is sweating, oiliness or hair thinning?
It matters because the evidence differs by purpose: a 2025 review described a consistently reported effect for scalp sweating, an effect described as mild or not statistically significant for androgenetic hair loss, and a reported purpose share for scalp seborrhea without a paired outcome description. One name on a menu can cover outcomes that do not read the same way.
What does the evidence show for scalp sweating specifically?
A 2025 review of 40 reports and 689 patients described a consistently reported effect for scalp sweating across the cases it covered. That is evidence from case-level reports rather than from the controlled trials behind an approved label, so it sits at a different tier from the axillary hyperhidrosis indication that is approved.
What does the evidence show for androgenetic hair loss specifically?
The same 2025 review described the reported effect on androgenetic hair loss as mild or not statistically significant, even though hair loss made up the largest share of reported purposes in that review, at about 79.5%. A large share of reports does not, by itself, mean a strong reported effect.
What does the evidence show for scalp seborrhea?
The 2025 review counted scalp seborrhea at about 10% of the reported purposes across its 40 reports. The purpose breakdown records that share without pairing it with the kind of outcome description it gives separately for hair loss and scalp sweating.
How much clinical evidence exists for scalp toxin overall?
A 2023 systematic review identified 24 reports covering 309 patients, made up of case reports, clinical trials and case series, and described the evidence as highly variable in quality and mostly drawn from small observational studies. A 2025 review expanded that to 40 reports and 689 patients across the same general set of scalp purposes.
How does the toxin injection reduce sweating at the injection site?
It blocks the release of acetylcholine at the nerve terminal, the signal that drives the sweat glands, rather than removing the glands themselves — the mechanism described on the therapeutic BOTOX label for its approved axillary indication. The sources cited on this page describe that mechanism for sweat glands only, not for the oiliness or hair-thinning purposes.
How is this different from the axillary hyperhidrosis toxin already covered on this site?
Underarm hyperhidrosis toxin sits on an approved U.S. label indication with a defined patient description; scalp toxin, for any of its three purposes, has no equivalent approval in the sources cited here and is supported instead by the case reports and reviews described on this page. Same substance, different evidence tier.
What should be confirmed before agreeing to a scalp toxin injection?
Confirm the purpose first — sweating, oiliness or hair thinning — because the evidence differs by purpose, then the product name and dose, since neither is standardized by a scalp-specific label, and what the clinic’s plan is if an adverse reaction appears. Disclose previous botulinum toxin treatment, neuromuscular conditions, current medicines, allergies, and pregnancy or breastfeeding beforehand.
What area-related safety considerations come up for the scalp specifically?
The scalp sits close to the forehead and temple muscles and to nerves running through the area, a different neighbourhood from the underarm the approved indication is written for. The sources cited on this page do not set numbers on a scalp-specific side-effect profile, so headache and localized muscle weakness near the injection points are raised here as questions to bring to the injecting clinician rather than as figures this page can state.
Does an approval for this exist anywhere else that would apply in Korea?
None of the three sources cited on this page describes a regulatory approval for a scalp indication, in the United States or elsewhere. What they describe is reported clinical use gathered into two literature reviews, which is a different kind of record from an approval.
How Abijou works
We started in Gangnam in 2006 and the network now runs 17 branches across Korea. The line we work to is skin transformation woven into everyday life — care you can keep up with, rather than one dramatic change.
- Across the 17 branches in Seoul, Gyeonggi, Incheon and Busan: over 1,000 medical professionals and more than 350 certified medical devices
- Authentic products only, in appropriate amounts — the treatment is fitted to the condition, not to a package
- Prices are quoted from each branch’s published price list as it stands
Contact and location
- Phone
- 1544-0377
Free Consultation
Booking happens at the branch
There is no inquiry form on this page. Once you have picked a branch above, open that branch’s site or the official reservation center and choose a time yourself.
- No deposit and no online prepayment — everything is paid at the visit
- Per-treatment prices are published for each branch on the official reservation center
- English, Japanese and Chinese are supported alongside Korean